— Know what they know.
Not Investment Advice

MGNX NASDAQ

MacroGenics, Inc.
1W: -30.1% 1M: -39.9% 3M: -33.5% YTD: +51.5% 1Y: +32.6% 3Y: -49.6% 5Y: -87.5%
$2.44
+0.25 (+11.42%)
 
Weekly Expected Move ±21.5%
$1 $2 $2 $3 $3
NASDAQ · Healthcare · Biotechnology · Tech Score Sell · Power 30 · $155.4M mcap · 56M float · 1.47% daily turnover · Short 47% of daily vol
Credit Risk of going bust: higher than 84% of companies Debt: 18.4% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the second-riskiest tenth, about 1 in 87 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.11 (down 96%), MacroGenics, Inc. would be worth roughly what it owes.
Total debt $35.1M against a stock market value of $155.4M.
Distance to default 2.26 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $20.0M (short-term plus half of long-term), stock volatility 92.7%; Altman Z'' -9.42. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Balance Sheet Trends

Total Assets
$257M -1.8% ▼
5Y CAGR: -7.5%
Total Liabilities
$201M +38.2% ▲
5Y CAGR: +19.4%
Shareholders Equity
$56M -52.1% ▼
5Y CAGR: -28.4%
Cash & Investments
$190M -5.8% ▼
5Y CAGR: -7.0%
Total Debt
$107M +185.0% ▲
5Y CAGR: +29.6%
Net Debt
$50M +134.1% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$123M$109M$101M$183M$57M
Short-Term Investments$120M$45M$129M$19M$133M
Cash & ST Investments$244M$154M$230M$202M$190M
Net Receivables$10M$56M$10M$4M$13M
Inventory$4M$1M$1M$0$8M
Other Current Assets$0$10M$10M$12M$9M
Total Current Assets$280M$222M$251M$217M$220M
Property, Plant & Equip.$54M$57M$46M$43M$36M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$1M$1M$1M$10M$1M
Total Non-Current Assets$56M$67M$47M$53M$37M
Total Assets$335M$290M$298M$262M$257M
— Liabilities —
Accounts Payable$16M$5M$6M$5M$5M
Short-Term Debt$0$5M$0$0$5M
Deferred Revenue$0$10M$22M$16M$11M
Other Current Liabilities$21M$29M$0$0$22M
Total Current Liabilities$75M$49M$56M$56M$43M
Long-Term Debt$0$0$0$0$70M
Other Non-Current Liab.$258K$258K$258K$2M$1M
Total Non-Current Liabilities$21M$99M$90M$99M$158M
Total Liabilities$96M$147M$146M$146M$201M
— Equity —
Common Stock$613K$617K$621K$628K$633K
Retained Earnings-$974M-$1.1B-$1.1B-$1.2B-$1.2B
Accumulated OCI-$61K-$5K-$6K$4K$32K
Total Stockholders Equity$240M$142M$153M$116M$56M
Total Liabilities & Equity$335M$290M$298M$262M$257M
— Key Metrics —
Total Debt$25M$35M$34M$37M$107M
Net Debt-$98M-$74M-$67M-$145M$50M
Total Investments$120M$45M$129M$19M$133M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms